Arck PC, et al. “The Alchemy of Immune Privilege Explored from a Neuroimmunological Perspective,” Current Opinions in Pharmacology (Aug. 2008): Vol. 8, No. 4, pp. 480–89. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18603017

Boulanger LM, et al. “Immune Signalling in Neural Development, Synaptic Plasticity and Disease,” Nature Reviews of Neuroscience (July 2004): Vol. 5, No. 7, pp. 521–31. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15208694

Dantzer R, et al. “From Inflammation to Sickness and Depression: When the Immune System Subjugates the Brain,” Nature Reviews of Neuroscience (Jan. 2008): Vol. 9, No. 1, pp. 46–56. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18073775

Dickinson D, et al. “Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on an Old Problem,” American Journal of Psychiatry (March 2009): Vol. 35, No. 2, pp. 403–14.

Fan X, et al. “Inflammation and Schizophrenia,” Expert Reviews of Neurotherapies (July 2007): Vol. 7, No. 7, pp. 789–96. www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed/17610386?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Fan X, et al. “Elevated Serum Levels of C-Reactive Protein are Associated with More Severe Psychopathology in a Subgroup of Patients with Schizophrenia,” Psychiatry Research (Jan. 15, 2007): Vol. 149, Nos. 1–3, pp. 57–66. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17610386

Fourgeaud L, et al. “Synapse Remodeling, Compliments of the Complement System,” Cell (Dec. 14, 2007): Vol. 131, No. 6, pp. 1034–36. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18083091

Gaynes BN, et al. “The STAR*D Study: Treating Depression in the Real World,” Cleveland Clinic Journal of Medicine (January 2008): Vol. 75, No. 1, pp. 57–66. www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/sites/entrez?orig_db=PubMed&db=pubmed&cmd=Search&term=57[page] AND 2008[pdat] AND gaynes[author]

The International Schizophrenia Consortium. “Common Polygenic Variation Contributes to Risk of Schizophrenia and Bipolar Disorder,” Nature (Electronic publication July 1, 2009; ahead of print). www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/pubmed/19571811?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Kuehn BM. “Scientists Probe Immune System's Role in Brain Function and Neurological Disease,” Journal of the American Medical Association (Feb. 13, 2008): Vol. 299, No. 6, pp. 619–20. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18270346

McAllister CG, et al. “Increases in CSF levels of Interleukin-2 in Schizophrenia: Effects of Recurrence of Psychosis and Medication Status,” American Journal of Psychiatry (Sept. 1995): Vol. 152, No. 9, pp. 1291–97. www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/sites/entrez?orig_db=PubMed&db=pubmed&cmd=Search&term=1291[page] AND 1995[pdat] AND McAllister[author]

Mendlewicz J, et al. “Shortened Onset of Action of Antidepressants in Major Depression Using Acetylsalicylic Acid Augmentation: A Pilot Open-Label Study,” International Clinical Psychopharmacology (July 2006): Vol. 21, No. 4, pp. 227–31. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16687994s

Miller AH, et al. “Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression,” Biological Psychiatry (May 1, 2009): Vol. 65, No. 9, pp. 732–41. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19150053

Muller N, et al. “The Cyclooxygenase-2 Inhibitor Celecoxib Has Therapeutic Effects in Major Depression: Results of a Double-Blind, Randomized, Placebo Controlled, Add-On Pilot Study to Reboxetine,” Molecular Psychiatry (July 2006): Vol. 11, No. 7, pp. 680–84. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16491133

Niebuhr DW, et al. “Selected Infectious Agents and Risk of Schizophrenia Among U.S. Military Personnel,” American Journal of Psychiatry (Jan. 2008): Vol. 165, No. 1, pp. 99–106. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18086751

Raison CL, et al. “Cytokines Sing the Blues: Inflammation and the Pathogenesis of Depression,” Trends in Immunology (Jan. 2006): Vol. 27, No. 1, pp. 24–31. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16316783

Stevens B, et al. “The Classical Complement Cascade Mediates CNS Synapse Elimination,” Cell (Dec. 14, 2007): Vol. 131, No. 6, pp. 1164–78. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18083105

Torrey EF, et al. “Antibodies to Toxoplasma Gondii in Patients with Schizophrenia: A Meta-Analysis,” Schizophrenia Bulletin (May 2007): Vol. 33, No. 3, pp. 729–36. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16687994

Tyring S, et al. “Etanercept and Clinical Outcomes, Fatigue, and Depression in Psoriasis: Double-Blind Placebo-Controlled Randomised Phase III Trial,” Lancet (Jan. 7, 2006): Vol. 367, No. 9504, pp. 29–35. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16399150

Van den Biggelaar AH, et al. “Inflammation and Interleukin-1 Signaling Network Contribute to Depressive Symptoms but not Cognitive Decline in Old Age,” Experimental Gerontology (July 2007): Vol. 42, No. 7, pp. 693–701. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17350781

Wenner M. “Infected with Insanity: Could Microbes Cause Mental Illness?” Scientific American (April 17, 2008), accessed online at www.sciam.com.

Yolken RH, et al. “Are Some Cases of Psychosis Caused by Microbial Agents? A Review of the Evidence,” Molecular Psychiatry (May 2008): Vol. 13, No. 5, pp. 470–9. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18268502

Zhang XY, et al. “Changes in Serum Interleukin-2, -6, and -8 Levels Before and During Treatment with Risperidone and Haloperidol: Relationship to Outcome in Schizophrenia,” Journal of Clinical Psychiatry (July 2004): Vol. 65, No. 7, pp. 940–07.